Clinical Trials / Research Studies
Neurofibromatosis Plexiform Neurofibroma

Neurofibromatosis Plexiform Neurofibroma

NF113: Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas

  • Ages: 16 Years and older

Based on the clinical activity of both selumetinib and cabozantinib as monotherapies in clinical trials, the demonstrated activity of these agents in reduced doses in preclinical studies, and the non-overlapping toxicity profiles, the study will assess the tolerability and efficacy of selumetinib an ...More

NF114: Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

  • Ages: 1 Year to 8 Years

Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was based on the finding that selumetinib shrinks the majority of PN in children with NF1 and results in cl ...More

NF119: A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 (INSPIRE-NF1)

  • Ages: 12 Years and older

The trial will be an open label, single arm, phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN. NF119: A Phase 2, Open-Label, Single Arm, Non-Controlled, Single-S ...More

Contact Us

Contact us.

To learn more about available clinical trials related to brain and spinal tumors, contact us at cancer@cchmc.org or 513-636-2799.

Related Studies

Give Today

3333 Burnet Avenue, Cincinnati, Ohio 45229-3026

© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.

U.S. News & World Report Honor Roll Badge for Top Children's Hospital.Best Places to Work.America's Best Large Employers